Pharmacists play a central role in how medicines are used at the point of care, particularly in the adoption of generics and biosimilars. While regulatory authorities ensure that these medicines meet established standards for quality, safety, and efficacy, their practical use is often shaped by how they are dispensed and explained to patients. In this way, pharmacists act as a critical bridge between regulatory approval and real-world patient experience.
One of the most direct ways pharmacists support access is through substitution practices. In South Africa, pharmacists are permitted, within defined regulatory parameters, to substitute a prescribed medicine with an equivalent generic alternative, provided there are no clinical restrictions indicated by the prescriber. This enables more efficient use of available medicines and supports affordability without compromising therapeutic outcomes. In the case of biosimilars, substitution is more structured and guided by clinical considerations, but pharmacists remain involved in supporting appropriate use and continuity where treatment changes occur.
Beyond substitution, patient engagement is a key component of pharmacist-led support. Differences in packaging, naming conventions, or physical appearance between medicines can create uncertainty, particularly for patients managing long-term conditions. Pharmacists provide clarity by explaining active ingredients, confirming dosage instructions, and reinforcing that approved generics and biosimilars meet the same regulatory standards as their reference products. This interaction helps reduce confusion, supports adherence, and builds confidence in treatment.
Pharmacists also contribute to clinical continuity by responding to supply dynamics within the system. Their awareness of stock availability, supply constraints, and alternative options allows them to guide appropriate substitutions when needed, ensuring that treatment is not interrupted. This role is particularly important in environments where medicine availability may vary across facilities or over time.
In addition, pharmacists play a role in pharmacovigilance by monitoring patient responses to medicines and identifying any concerns that may arise during use. This contributes to the broader safety monitoring system and ensures that any issues are addressed in a timely and structured manner.
The adoption of generics and biosimilars is therefore supported not only by regulatory processes but also by consistent application at the point of dispensing. Through substitution practices, patient education, and clinical support, pharmacists contribute to a more informed and responsive healthcare environment. Their role supports both access to treatment and confidence in the medicines used across the healthcare system.